Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05874479 · ClinicalTrials.gov registry record · NA
Reducing AIR Pollution Exposure to Lower Blood PRESSURE Among New York City Public Housing Residents
A NA study of Blood Pressure, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 440
- Enrollment target
- 1
- Study location
NCT05874479: Recruiting NA study of Blood Pressure, sponsored by NYU Langone Health.
NCT05874479 is a NA study of Blood Pressure that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 440 participants, above the 283-participant average among 101 other Blood Pressure trials with a reported enrollment target (55% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05874479, a NA study of Blood Pressure, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 440 participants
- Enrollment target
- 1
- Study location
Study Summary
Fine particulate matter \<2.5 µm (PM2.5) air pollution is the fifth leading risk factor for global mortality, with the largest portion of deaths due to cardiovascular disease (CVD). While several mechanisms are responsible, PM2.5-induced elevations in blood pressure (BP) may be relevant. Indoor portable air cleaners (PACs) are a novel approach to reduce exposure to PM2.5 and potentially lower blood pressure. The current study is being conducted to provide evidence that PACs reduce PM2.5 exposure and lower systolic blood pressure (SBP) in key patient populations.
Primary Outcome
Participants measure HBP every day between 6-9 am.
Conditions Studied
Interventions
- DEVICE Active PAC
- DEVICE Sham PAC
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2023-12-20 |
| Est. Completion | 2028-03 |
| Phase | NA |
What NCT05874479 shows while recruiting
NCT05874479 is an interventional study that assigns participants to a tested intervention. The registered 440 participants enrollment target is mid-sized for trials with a published cap, above the 283-participant average among 101 other Blood Pressure trials with a reported enrollment target (55% higher).
The record links to 1 condition, with Blood Pressure appearing as the primary indexed condition, and to 2 interventions - of which Active PAC is the first listed.
NCT05874479 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05874479 about?
NCT05874479 is a clinical study titled "Reducing AIR Pollution Exposure to Lower Blood PRESSURE Among New York City Public Housing Residents". Fine particulate matter \<2.5 µm (PM2.5) air pollution is the fifth leading risk factor for global mortality, with the largest portion of deaths due to cardiovascular disease (CVD). While several mechanisms are responsible, PM2.5-induced elevations in blood pressure (BP) may be relevant. Indoor port...
What is the current status of trial NCT05874479?
This trial is currently recruiting. It is a NA study. The enrollment target is 440 participants. The study started on 2023-12-20. Estimated completion is 2028-03.
What conditions does trial NCT05874479 study?
This clinical trial studies the following conditions: Blood Pressure.
What interventions are being tested in trial NCT05874479?
The interventions under investigation include: Active PAC (DEVICE), Sham PAC (DEVICE).
Who is sponsoring clinical trial NCT05874479?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05874479 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blood Pressure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05874479's enrollment target sits among peer trials
440 11th of 101 higher than 91 of 101 other Blood Pressure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Blood Pressure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Cocooned Moms Study
RECRUITING · NA
-
The GUARDIAN Trial
RECRUITING · NA
-
The Venous Distension Reflex and Orthostatic Hypertension
RECRUITING · NA
-
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
RECRUITING · NA
-
The Effect of Transcutaneous Stimulation on Blood Pressure in Spinal Cord Injury (SCI)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
- NCT05117619 · 440 participants · NA
The HOME Program for Individuals With Traumatic Brain Injury and Family Members
- NCT05602194 · 440 participants · Phase 3
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
- NCT05624879 · 440 participants · NA
Accelerated Resolution Therapy for Early Maladaptive Grief
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI